Extended diagnostic criteria for plasmacytoid dendritic cell leukaemia

Summary The diagnosis of plasmacytoid dendritic cell leukaemia (pDCL) is based on the immunophenotypic profile: CD4+ CD56+ lineageneg CD45RA+/ROneg CD11cneg CD116low CD123+ CD34neg CD36+ HLA‐DR+. Several studies have reported pDCL cases that do not express this exact profile or expressing some lineage antigens that could thus be misdiagnosed. This study aimed to validate pDCL‐specific markers for diagnosis by flow‐cytometry or quantitative reverse transcription polymerase chain reaction on bone marrow samples. Expression of markers previously found in normal pDC was analysed in 16 pDCL, four pDCL presenting an atypical phenotype (apDCL) and 113 non‐pDC – lymphoid or myeloid – acute leukaemia. CD123 was expressed at significantly higher levels in pDCL and apDCL. BDCA‐2 was expressed on 12/16 pDCL and on 2/4 apDCL, but was never detected in the 113 non‐pDC acute leukaemia cases. BDCA‐4 expression was found on 13/16 pDCL, but also in 12% of non‐pDC acute leukaemia. High levels of LILRA4 and TCL1A transcripts distinguished pDCL and apDCL from all other acute leukaemia (except B‐cell acute lymphoblastic leukaemia for TCL1A). We thus propose a diagnosis strategy, scoring first the CD4+ CD56+/− MPOneg cCD3neg cCD79aneg CD11cneg profile and then the CD123high, BDCA‐2 and BDCA‐4 expression. Atypical pDCL can be also identified this way and non‐pDC acute leukaemia excluded: this scoring strategy is useful for diagnosing pDCL and apDCL.